MedTrace Logo

Comparison of IPACK Block and PCI for Postoperative Analgesia and Function Recovery Following Total Knee Arthroplasty

NCT05943080 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 195

Last updated 2024-03-07

No results posted yet for this study

Summary

It was planned to determine the most effective single and/or combined use in daily use by evaluating the effect on pain control and functional status by combining the posterior capsuler infiltration (PCI) and interspace between the popliteal artery and the capsule of the posterior knee(IPACK block) performed during total knee replacement surgery with the adductor canal block method.

In the randomized controlled study:

Group 1; By determining the anatomical landmarks to be applied by the intraoperative surgeon, PCI + Adductor canal block (ACB) without any additional imaging, Group 2; IPACK+ACB applied by the anesthesiologist with the help of post-operative USG, In Group 3, there are 3 groups in which only ACB application is made. VAS values and opioid consumption of the groups will be recorded as the primary outcome after the surgery.

As a secondary outcome, the 1st day rehabilitation initiation times and endurance of the patients With 1.2. and on Day 3 joint ranges of motion will be recorded.

Conditions

  • Total Knee ArthroplastyKnee Pain, Functionality

Interventions

DRUG

PCI (0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline)

The application is made into the anatomical space between the posterior capsule and the popliteal artery before implantation.

DRUG

IPACK(0.25% marcaine+ 2.0 μg/mL of adrenaline + %0.9 saline)

It is applied to the anatomical space between the posterior capsule and the popliteal artery with the help of USG.

DRUG

ACB ( 0.25% marcaine + %0.9 saline)

It is inserted into the adductor canal by simultaneous imaging of the needle, accompanied by ultrasonography, from the level just below the sartorius muscle.

Sponsors & Collaborators

  • Kirsehir Ahi Evran Universitesi

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2023-08-10
Completion
2023-12-15

Countries

  • Turkey (Türkiye)

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05943080 on ClinicalTrials.gov